Breast Cancer, FGFR2

View:
Expand Collapse Breast Cancer  - General Description Breast cancer is the most common non-cutaneous cancer among women in the United States. This year about 252,710 women in the U.S. will be told by a doctor that they have breast cancer. Half of these people will be at least 62 years old. However, an estimated 3,327,552 women are living with female breast cancer in the United States following treatment.

Germline mutations in either the BRCA1 or BRCA2 gene confer an increased risk of breast and/or ovarian cancer. In addition, mutation carriers may be at increased risk of other primary cancers. Genetic testing is available to detect mutations in members of high-risk families. Such individuals should first be referred for counseling. Breast cancer is commonly treated by various combinations of surgery, radiation therapy, chemotherapy and hormone therapy.

Over the past years, significant major strides in understanding the biology of breast cancer have translated into actionable targeted therapies. For metastatic hormone receptor positive breast cancer, FDA approved therapies include tamoxifen, a selective estrogen modulator, aromatase inhibitors including exemestane, letrozole, and anastrozole, fulvestrant, a selective estrogen receptor blocker, and more recently everoliumus, a mTOR inhibitor, in combination with exemestane.

Despite significant improvements in the treatment of breast tumors, novel therapies and treatment strategies are needed. There are a number of novel therapies in development tailored to specific somatic mutations in the tumor.

Source: National Cancer Institute, 2017
Breast cancer is the most common non-cutaneous cancer among women in the United States. This year about 252,710 women in the U.S. will be told by a doctor that they have breast cancer. Half of these people will be at least 62 years old. However, an estimated 3,327,552 women are living with female breast cancer in the United States following treatment.

Germline mutations in either the BRCA1 or BRCA2 gene confer an increased risk of breast and/or ovarian cancer. In addition, mutation carriers may be at increased risk of other primary cancers. Genetic testing is available to detect mutations in members of high-risk families. Such individuals should first be referred for counseling. Breast cancer is commonly treated by various combinations of surgery, radiation therapy, chemotherapy and hormone therapy.

Over the past years, significant major strides in understanding the biology of breast cancer have translated into actionable targeted therapies. For metastatic hormone receptor positive breast cancer, FDA approved therapies include tamoxifen, a selective estrogen modulator, aromatase inhibitors including exemestane, letrozole, and anastrozole, fulvestrant, a selective estrogen receptor blocker, and more recently everoliumus, a mTOR inhibitor, in combination with exemestane.

Despite significant improvements in the treatment of breast tumors, novel therapies and treatment strategies are needed. There are a number of novel therapies in development tailored to specific somatic mutations in the tumor.

Source: National Cancer Institute, 2017
Breast cancer is the most common non-cutaneous cancer among women in the United States. This year about 252,710 women in the U.S. will be told by a doctor that they have breast cancer. Half of these people will be at least 62 years old. However, an estimated 3,327,552 women are living with female breast cancer in the United States following treatment.

Germline mutations in either the BRCA1 or BRCA2 gene confer an increased risk of breast and/or ovarian cancer. In addition, mutation carriers may be at increased risk of other primary cancers. Genetic testing is available to detect mutations in members of high-risk families. Such individuals should first be referred for counseling. Breast cancer is commonly treated by various combinations of surgery, radiation therapy, chemotherapy and hormone therapy.

Over the past years, significant major strides in understanding the biology of breast cancer have translated into actionable targeted therapies. For metastatic hormone receptor positive breast cancer, FDA approved therapies include tamoxifen, a selective estrogen modulator, aromatase inhibitors including exemestane, letrozole, and anastrozole, fulvestrant, a selective estrogen receptor blocker, and more recently everoliumus, a mTOR inhibitor, in combination with exemestane.

Despite significant improvements in the treatment of breast tumors, novel therapies and treatment strategies are needed. There are a number of novel therapies in development tailored to specific somatic mutations in the tumor.

Source: National Cancer Institute, 2017
Breast cancer is the most common non-cutaneous cancer among women in the United States. This year about 252,710 women in the U.S. will be told by a doctor that they have breast cancer. Half of these people will be at least 62 years old. However, an estimated 3,327,552 women are living with female breast cancer in the United States following treatment.

Germline mutations in either the BRCA1 or BRCA2 gene confer an increased risk of breast and/or ovarian cancer. In addition, mutation carriers may be at increased risk of other primary cancers. Genetic testing is available to detect mutations in members of high-risk families. Such individuals should first be referred for counseling. Breast cancer is commonly treated by various combinations of surgery, radiation therapy, chemotherapy and hormone therapy.

Over the past years, significant major strides in understanding the biology of breast cancer have translated into actionable targeted therapies. For metastatic hormone receptor positive breast cancer, FDA approved therapies include tamoxifen, a selective estrogen modulator, aromatase inhibitors including exemestane, letrozole, and anastrozole, fulvestrant, a selective estrogen receptor blocker, and more recently everoliumus, a mTOR inhibitor, in combination with exemestane.

Despite significant improvements in the treatment of breast tumors, novel therapies and treatment strategies are needed. There are a number of novel therapies in development tailored to specific somatic mutations in the tumor.

Source: National Cancer Institute, 2017
Expand Collapse FGFR2  - General Description
CLICK IMAGE FOR MORE INFORMATION
FGFR is a gene that provides the code for making a protein called fibroblast growth factor receptor. This receptor is located on the surface of cells. FGFR has at least 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) bind to an FGFR receptor, this activates a signaling system within the cell that causes the cell to undergo certain changes. In their normal role, the FGFR proteins play crucial roles in cell proliferation, migration, angiogenesis, and survival.

In certain types of cancers, genetic changes in the FGFR gene have been found. These changes include either amplification (more of the receptor is made than in normal cells), translocation (the gene has moved position such that it is under different regulation, causing more of the receptor to be made than in normal cells), or mutation (changes in the DNA that result in dysregulation of the protein, usually causing continuous activation of the receptor, even in the absence of growth factor). The excessive signaling that results from these genetic changes in number or activity level of the FGFR receptors contribute to abnormal cell growth and cancer. Unusual expression of the FGFR2 gene from various gene alterations has been found in some Breast cancers, Bladder cancers, Colorectal cancers, Esophageal/Gastric cancers, Endometrial cancers, Gall Bladder and Bile Duct (Cholangiocarcinoma) cancers, Glioblastomas, Head and Neck cancers, Lung cancers, Ovarian cancers, Pancreatic cancer, and Prostate cancer.

Preclinical testing in cancer cell lines suggest that FGFR gene alterations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR genetically altered tumors, with treatment of patients in these early studies underway.

FGFR is a gene that provides the code for making a protein called fibroblast growth factor receptor. This receptor is located on the surface of cells. FGFR has at least 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) bind to an FGFR receptor, this activates a signaling system within the cell that causes the cell to undergo certain changes. In their normal role, the FGFR proteins play crucial roles in cell proliferation, migration, angiogenesis, and survival.

In certain types of cancers, genetic changes in the FGFR gene have been found. These changes include either amplification (more of the receptor is made than in normal cells), translocation (the gene has moved position such that it is under different regulation, causing more of the receptor to be made than in normal cells), or mutation (changes in the DNA that result in dysregulation of the protein, usually causing continuous activation of the receptor, even in the absence of growth factor). The excessive signaling that results from these genetic changes in number or activity level of the FGFR receptors contribute to abnormal cell growth and cancer. Unusual expression of the FGFR2 gene from various gene alterations has been found in some Breast cancers, Bladder cancers, Colorectal cancers, Esophageal/Gastric cancers, Endometrial cancers, Gall Bladder and Bile Duct (Cholangiocarcinoma) cancers, Glioblastomas, Head and Neck cancers, Lung cancers, Ovarian cancers, Pancreatic cancer, and Prostate cancer.

Preclinical testing in cancer cell lines suggest that FGFR gene alterations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR genetically altered tumors, with treatment of patients in these early studies underway.

PubMed ID's
24265351
Expand Collapse FGFR2  in Breast Cancer
Testing in cancer cell lines as well as patient tumors suggests that genetic alterations in the FGFR2 gene can contribute to breast cancers. Gene amplifications as well as activating gene mutations have been found in different tumors. This may be an important mechanism of tumor progression, which has led to the development of clinical trials evaluating FGFR inhibitors in FGFR2-amplified or FGFR2-mutated breast cancers, which are currently underway.

Testing in cancer cell lines as well as patient tumors suggests that genetic alterations in the FGFR2 gene can contribute to breast cancers. Gene amplifications as well as activating gene mutations have been found in different tumors. This may be an important mechanism of tumor progression, which has led to the development of clinical trials evaluating FGFR inhibitors in FGFR2-amplified or FGFR2-mutated breast cancers, which are currently underway.


Expand Collapse No mutation selected
The mutation of a gene provides clinicians with a very detailed look at your cancer. Knowing this information could change the course of your care. To learn how you can find out more about genetic testing please visit http://www.massgeneral.org/cancer/news/faq.aspx or contact the Cancer Center.
Our Breast Cancer Team

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (D) - Disease, (G) - Gene
Trial Status: Showing Results: 1-10 of 44 Per Page:
12345Next »
Protocol # Title Location Status Match
NCT02684032 A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer MGH Open DG
NCT02734615 Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers MGH Open DG
NCT01872260 Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer MGH Open DG
NCT02732119 Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. MGH Open DG
NCT01296555 A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer MGH Open D
NCT02052778 A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities MGH Open D
NCT02580448 A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer MGH Open D
NCT02715284 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors MGH Open D
NCT02099058 A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors MGH Open D
NCT02338349 A Phase I, Multicenter, Open-Label, Two-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer A Phase I, Multicenter, Open-Label, Two-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer MGH Open D
Trial Status: Showing Results: 1-10 of 44 Per Page:
12345Next »
Our Breast Cancer Team

Share with your Physican

Print information for your Physician.

Print information